<p>|Recommendations|Certainty of evidence|Evidence report(s) of the following PICO(s)†|Supplementary Appendix 2|
|---|---|---|---|
|Initiation of treatment in DMARD-naive patients with moderate-to-high disease activity| | | |
|Methotrexate monotherapy is strongly recommended over:| | | |
|Hydroxychloroquine or sulfasalazine|Very low/low‡|PICO 2a.C1/C2|p. 14–5|
|bDMARD or tsDMARD monotherapy|Very low/moderate|PICO 5a.C1–4/C5§|p. 61–78|
|Combination of methotrexate plus a non–TNF inhibitor bDMARD or tsDMARD¶|Low/very low|PICO 6a.C2–4/C5§|p. 109, 117–28|
|Methotrexate monotherapy is conditionally recommended over:| | | |
|Leflunomide|Low|PICO 2a.C3|p. 18|
|Dual or triple csDMARD therapy¶|Moderate|PICO 4a.C1–C2|p. 46–9|
|Combination of methotrexate plus a TNF inhibitor¶|Low|PICO 6a.C1|p. 110|
|Initiation of a csDMARD without short-term (&lt;3 months) glucocorticoids is conditionally recommended over initiation of a csDMARD with short-term glucocorticoids.|Very low|PICO 7a|p. 167|